FRAME SIGNED

Project "FRAME" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Frame Cancer Therapeutics is a Dutch start-up that develops effective vaccines against cancer, based on frameshift mutations. Driven by the ambition to provide a therapeutic effect for up to 50% of all cancers, Frame aims to alter the status quo of cancer treatment. Our balanced team consists of top researchers and successful biotech entrepreneurs with a track record including the CEO of Crucell , and founder of ProQR.

The clinical use of so-called checkpoint inhibitors, which activate the immune system, has shown great effects, particularly for treatment of advanced melanoma. Yet, a large group of cancer patients does not benefit from this treatment alone, and the next step is to combine this general activation of the immune system with tumor-specific vaccination. This has just become possible now that entire tumor DNA sequences get to be routinely read within two weeks, as part of clinical care.

The solution that Frame Cancer Therapeutics has developed is a ground-breaking strategy for anti-cancer vaccination using off-the-shelf yet personalized cancer vaccines derived from frameshift mutations. Frame Therapeutics has discovered FRAMES, a source of shared neoantigens induced by frame-shift mutations with unique therapeutic potential. These sequences are usually not expressed in the healthy body, and thus seen as foreign by the immune system. A licensed sets of FRAMES are each specific vaccines for different tumor types (such as breast, lung, kidney, colon, uterine cancer).

Most cancer vaccination strategies are based on point mutations unique for each tumor, requiring costly individualized vaccine manufacturing. Frame Therapeutics is the first company entirely focusing on the development of cancer vaccines based on FRAMES, offering off-the-shelf personalized cancer vaccines. This approach allows for economics of scale, reducing time to treatment from months to days, which is critical to patient health, and which will imprcost/benefit ratio’s.